Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Summary

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.

Interventions

• 68Ga-FAPI-46 for PET / CT scan · DRUG

  Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

1. Cyto/histologically proven PDAC
2. Non-metastatic proven PDAC on recent (\< 1 month) CT-scan and MRI
3. Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)
4. Age \> 18 years old
5. Affiliation to a social security scheme
6. Signed informed consent

Exclusion Criteria:

1. Protected adults (guardianship, curatorship or safeguarding justice)
2. Pregnant or breastfeeding woman
3. Women of childbearing potential not using one highly effective method of contraception

Sites (1)

• Institut Curie -site Saint-Cloud, Saint-Cloud, France · RECRUITING